Proactive Investors - Run By Investors For Investors

Sareum to further develop ‘potential best-in-class’ autoimmune disease treatment

Sareum thinks SDC-1801 is the most potent in the series of compounds and will now take it through pre-clinical development before advancing into human trials, which could begin as early as 2020
scientist in lab
The likes of Pfizer and Bristol-Myers Squibb are also developing TYK2 inhibitors

Sareum Holdings Plc (LON:SAR) has selected a candidate molecule to take through the clinic which it thinks could become the new, "potentially best-in-class" treatment for autoimmune diseases.

SDC-1801 has shown “compelling activity” in disease models of psoriasis and rheumatoid arthritis, while AIM-listed Sareum also noted the potential for once-daily oral dosing and a good early safety profile.

Closely related molecules have also shown “good activity” in models of inflammatory bowel disease and lupus.

READ: Sareum receives update on progress of cancer drug

“These attributes strongly support the progression of SDC-1801 into preclinical development and, pending satisfactory progress, advancement into human clinical trials, which could begin in 2020,” the statement said.

SDC-1801 works by targeting the TYK2 and JAK1 enzymes which are known to have roles in pro-inflammatory responses in autoimmune diseases and tumour cell proliferation in certain cancers.

A second, ‘back-up’ candidate is expected to be nominated in the near future.

“With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features,” said chief executive Tim Mitchell.

“We intend to focus our resources on advancing SDC-1801 through preclinical development and into clinical trials over the next 18 months. At the same time, we will continue our discussions with potential licence partners for this exciting drug candidate.”

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Big Picture
February 22 2019

Related Articles

Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Cancer cells
February 12 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use